Backyard Gene Editing Risks Creating a Monster
March 21, 2017
(New Scientist) – In reality, the FDA is walking a fine line, trying to keep abreast of a fast-moving field without stifling innovation. It cannot allow the biohacker tail to wag the CRISPR dog. But the problem requires a more sophisticated response than retrofitting old laws to new problems.